Skip to content
FORSIDEN
Log ind Opret konto
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — September 2025

Genmab — September 2025

Planlagt Fastgjort Låst Flyttet Genmab
283 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • R Offline
    R Offline
    Raun
    wrote on sidst redigeret af
    #230

    Har nu også tillid til Genmab's expertise.... Tror ikke på at de vil købe, hvis de ikke var 99-100% sikker på succes... Men de SKAL også være så sikre, når de smider så mange penge..

    1 Reply Last reply
    0
    • P Offline
      P Offline
      ProinvestorNEWS
      wrote on sidst redigeret af
      #231

      Genmabs topchef om gigantopkøb: Timingen er perfekt https://proinvestor.com/investornyt/1366245/genmabs-topchef-om-gigantopkob-timingen-er-perfekt

      1 Reply Last reply
      0
      • P Offline
        P Offline
        ProinvestorNEWS
        wrote on sidst redigeret af
        #232

        Genmab hæves til "køb" efter kæmpeopkøb af Sydbank https://proinvestor.com/investornyt/1366244/genmab-haeves-til-kob-efter-kaempeopkob-af-sydbank

        1 Reply Last reply
        0
        • G Offline
          G Offline
          Goose3
          wrote on sidst redigeret af
          #233

          Novo har sendt BLA ind på Mim8. Mener Genmab får en ciffer royalties på produktet.

          1 Reply Last reply
          0
          • J Offline
            J Offline
            JKY_VH
            wrote on sidst redigeret af
            #234

            Jan er den C25-CEO med hænderne mest på kogepladen, så han har i høj grad privatøkonomiske interesser på spil.

            1 Reply Last reply
            0
            • R Offline
              R Offline
              Raun
              wrote on sidst redigeret af
              #235

              Mon vi skal ende i plus?

              1 Reply Last reply
              0
              • SolsenS Offline
                SolsenS Offline
                Solsen
                wrote on sidst redigeret af
                #236

                Genmab kunne ikke have købt for et par måneder siden. Så havde jorden rystet under dem. Timing er alt 😉

                1 Reply Last reply
                0
                • L Offline
                  L Offline
                  LP90
                  wrote on sidst redigeret af
                  #237

                  shorts er steget med 0,10% i dag ???

                  1 Reply Last reply
                  0
                  • R Offline
                    R Offline
                    Raun
                    wrote on sidst redigeret af
                    #238

                    @Solsen kl.16.11 - Meget enig 🙂

                    1 Reply Last reply
                    0
                    • BulderB Offline
                      BulderB Offline
                      Bulder
                      wrote on sidst redigeret af
                      #239

                      Udløser mim8 ikke en milepæl? Royalties er mid single digit.

                      1 Reply Last reply
                      0
                      • P Offline
                        P Offline
                        ProinvestorNEWS
                        wrote on sidst redigeret af
                        #240

                        Mandagens aktier: Genmab i udsat rolle i positivt C25 https://proinvestor.com/investornyt/1366319/mandagens-aktier-genmab-i-udsat-rolle-i-positivt-c25

                        1 Reply Last reply
                        0
                        • E Offline
                          E Offline
                          E_L
                          wrote on sidst redigeret af
                          #241

                          before the current CEO, merus had founder Ton Logtenberg as CEO. He is a Professor at Utrecht University, just like Jan. They go back a long time , for example this is an article they co-authored in 1999 https://aacrjournals.org/cancerres/article/59/22/5778/505642/Antitumor-Immune-Effector-Mechanisms-Recruited-by

                          1 Reply Last reply
                          0
                          • E Offline
                            E Offline
                            E_L
                            wrote on sidst redigeret af
                            #242

                            'H.C. Wainwright downgraded Merus (MRUS) to Neutral from Buy with a price target of $97, down from $135'

                            1 Reply Last reply
                            0
                            • E Offline
                              E Offline
                              E_L
                              wrote on sidst redigeret af
                              #243

                              Today’s deal was viewed favorably by industry observers, with William Blair analysts pointing to predicted peak sales of $3 billion to $4 billion for petosemtamab in head and neck cancer alone as proof that the acquisition is a “positive” for Genmab. https://www.fiercebiotech.com/biotech/genmab-pays-8b-buy-merus-and-phase-3-stage-bispecific-wowed-analysts

                              1 Reply Last reply
                              0
                              • R Offline
                                R Offline
                                Raun
                                wrote on sidst redigeret af
                                #244

                                Det giver jo god mening 🙂

                                1 Reply Last reply
                                0
                                • R Offline
                                  R Offline
                                  Raun
                                  wrote on sidst redigeret af
                                  #245

                                  Ovenstående som svar på E L kl. 20.11

                                  1 Reply Last reply
                                  0
                                  • R Offline
                                    R Offline
                                    Raun
                                    wrote on sidst redigeret af
                                    #246

                                    sorry kl. 20.06 🙂

                                    1 Reply Last reply
                                    0
                                    • E Offline
                                      E Offline
                                      E_L
                                      wrote on sidst redigeret af
                                      #247

                                      😉

                                      1 Reply Last reply
                                      0
                                      • E Offline
                                        E Offline
                                        E_L
                                        wrote on sidst redigeret af
                                        #248

                                        Leerink Partners raised its price target on Genmab A/S (NASDAQ:GMAB) to $34.00 from $32.00 on Monday, while maintaining an Outperform rating following the company’s proposed acquisition of Merus https://www.investing.com/news/analyst-ratings/leerink-partners-raises-genmab-stock-price-target-on-merus-acquisition-93CH-4261527

                                        1 Reply Last reply
                                        0
                                        • E Offline
                                          E Offline
                                          E_L
                                          wrote on sidst redigeret af
                                          #249

                                          New trial - Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/​Refractory Diffuse Large B-cell Lymphoma (DLBCL) (CLEAR) https://clinicaltrials.gov/study/NCT07197307

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper